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Abstract 
Review on PIK3CA, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
Keywords 
PIK3CA; Kinase; Cell proliferation; Differentiation 
Identity 
HGNC (Hugo): PIK3CA 
Location: 3q26.32 
Other names: EC 2.7.1.153, MGC142161, 
MGC14216, PI3K, p110-alpha 
Local order: centromere-KCNMB2- ZMAT3- 
LOC101928739-PIK3CA- KCNMB3- ZNF639- 
MFN1- GNB4- telomere 
DNA/RNA 
Description 
The PIK3CA gene spans a total genomic size of 
86,190 bases and is composed of 21 exons, 20 of 
them coding exons of varying lengths.  
Putative pseudogenes of PIK3CA have been 
described on chromosomes 16 (gi 28913054) and 
22q11.2 (gi 5931525), the later one in the Cat Eye 
Syndrome region.  
These regions are highly homolog to the sequences 
of exons 9 and 11-13 of the PIK3CA gene. 
Transcription 
The human PIK3CA transcript has an open reading 
frame of 3,207-bp, predicting a protein of 1,068 
amino acid residues. 
Pseudogene 
A pseudogene has been identified in chromosome 20 
(LOC100422375) spanning exons 9 to 13 with 95% 
homology in both exons and introns.  
A non-specific amplification of PIK3CA could result 
in a E545A false positive mutation which is the 
amino-acid most commonly mutated in PIK3CA. 
Relative size of the 21 exons of PIK3CA. The entire exon 1 is UTR (untranslated region). Exon numeration corresponds to the 
prevalent transcript (NM-006218). 
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha 
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The PIK3CA gene encodes the p110alpha protein 
which is a catalytic subunit of the class I PI 3-kinases 
(PI3K). Class I PI3K are heterodimeric molecules 
composed of a catalytic subunit, a p110, and a 
regulatory subunit. There are three possible calatytic 




The p110alpha localizes in the cytoplasm. 
Function 
Class I PI 3-kinases (PI3K) are one of the most 
prevalently dysregulated pathways in human cancer 
and it is linked to many cellular functions, including 
cell growth, proliferation, differentiation, motility, 
survival and intracellular trafficking. PI3K convert 
PI(4,5)P2 to PI(3,4,5)P3 on the inner leaflet of the 
plasma membrane. The PI(3,4,)P3 provokes the 
recruitment to cellular membranes of a variety of 
signalling proteins, containing PX domain, 
pleckstrin homology domains (PH domains), FYVE 
domains and other phosphoinositide-binding 
domains. One of these is the protein kinase B 
(PKB/AKT) a very well known protein that is 
activated as a result of its translocation to the cell 
membrane where it is then phosphorylated and 
activated by another kinase, called phosphoinositide 
dependent kinase 1 (PDK1). The phosphorylation of 
AKT leads to the activation of the TSC/mTOR 
pathway. Accordingly, PIK3CA and PTEN genetic 
alterations are usually alternative events. 
Mutations 
Somatic 
Somatic mutations at the PIK3CA gene have been 
found in tumors and thus, it is a bona fide oncogene 
(Samuels et al., 2004). Sequencing analyses of 
pancancer genomes suggests that PIK3CA has at 
least 19 mutational hotspots (Chang et al, 2016). 
Most mutations occur in two of the five domains of 
p110alpha, the helical and kinase domains. 
However, while there are no frequent hotspot 
mutations within the Ras-binding domain (RBD), 
hotspot mutations within the adaptor-binding 
domain (ABD) and the C2 domain are also 
frequently found. Hotspots Arg38 and Arg88 are 
located within the ABD at the interface with the 
kinase domain. These mutations disrupt hydrogen 
bonds between the domains which may alter the 
conformation of the kinase domain and therefore its 
enzymatic activity. Similarly, hotspots Asn345 and 
Glu453 within the C2 domain occur at the interface 
with the iSH2 domain of p85 and are expected to 
alter the interaction between these domains. Within 
the helical domain, the most common hotspots 
Glu542 and Glu545 are usually mutated into lysine 
and are located at the interface with the nSH2 
domain of p85. A structural model of the 
p110/niSH2 complex suggests that the contacts 
between these amino acids and the nSH2 domain 
occur within a region of the nSH2 domain which is 
also in contact with the kinase domain of p110. 
These contacts may serve as the mechanism by 
which the helical domain mutations alter the activity 
of the enzyme. In the kinase domain, His1047 is 
frequently mutated to arginine within a helix at the 
end of the activation loop. Another less frequent 
kinase mutation of Met1043 occurs within the same 
helix and likely has similar effects on enzymatic 
activity. Thr1025 mutations are located near the N-
terminus of the catalytic loop which may directly 
alter the conformation of the catalytic loop as the 
mechanism by which the mutation alters enzymatic 
activity (Huang, 2008). Two other hotspot positions, 
Lys111 and Gly118, are located outside of the five 
domains in the 81 residue linker between ABD and 
RBD (Chang, 2016).  
The distribution of PIK3CA hotspot mutations can 
be significantly variable across tumour types in the 
kinase and helical domain. For example, cervical and 
bladder cancers share similar distributions of 
hotspots but they have far fewer H1047R kinase 
mutations than breast cancer. Similarly, endometrial 
and colorectal cancers share distribution patterns but 
display more R88Q mutations than other tumor 
types, maybe because this change is a target mutation 
of POLE genomic instability. However, colorectal 
cancers differ from endometrial cancers in their 
clonality. In endometrial tumors, both E545 helical 
domain mutations and H1047 kinase domain 
mutations are early clonal mutations whereas in 
colorectal cancer several E545 mutations are 
subclonal and H1047 mutations clonal (Chang, 
2016).  
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha 
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The variation in hotspot distributions suggests 
different functions need to be targeted in different 
tumour types.  
Different domain mutations in PIK3CA have been 
associated with differential signaling. Kinase 
domain mutations have higher activation of PI3K 
complexes and increased G-alpha signaling events. 
However, some components of the G-alpha 
signaling pathway such as RHO GTPase complexes 
have lower activity in the kinase domain mutants 
relative to other PIK3CA mutants. Additionally, 
helical domain mutations are associated with lower 
activation of pathways related to proliferation, such 
as FOXM1, MYC, and PLK1, in comparison to other 
PIK3CA mutants. The different patterns of pathway 
activation associated with mutations of specific 
PIK3CA domains suggest that kinase domain 
mutations are more strongly associated with 
proliferation activity, whereas helical domain 
mutations are more strongly associated with motility 
activities. These differences in function across 
domain specific mutations may drive the varying 
distribution of mutations seen across cancer types 
(Yau, 2014). 
Epigenetics 
PIK3CA has a small CpG island in the gene 
promoter but no methylation has been described. 
Implicated in 
A wide variety of human cancers 
PIK3CA mutations lead to constitutive activation of 
p110alpha enzymatic activity, stimulate AKT 
signaling, and allow growth factor-independent 
growth (Bader et al., 2005). In addition, when 
expressed in normal cells, these mutations allow 
anchorage-independent growth, further attesting to 
their important role in cancer development (Kang et 
al., 2005). PIK3CA somatic mutations are frequent 
in a variety of human primary tumors and cancer cell 
lines such as, among others, those of the colon, 
breast, and stomach (Samuels et al., 2004). However, 
in other tumors, i.e. those of the lung, head and neck, 
brain, endometrium, ovary, prostate, osteosarcoma 
and pancreas, hematopoietic malignancies, PIK3CA 
mutations are not as common (Angulo et al., 2008; 
Qiu et al., 2006; Muller et al., 2007; Samuels et al., 
2004; Schonleben et al., 2006). PIK3CA gene 
amplification has also been proposed as a 
mechanism for oncogene activation in some tumors 
(Angulo et al., 2008). 
Cowden syndrome 
Disease 
Syndrome characterized by multiple noncancerous 
hamartomas and high predisposition to breast, 
thyroid and other tumour types. Germline PIK3CA 
mutations may account for around 10% of cases. 
Most of these mutations are in different positions to 
main hotspot somatic PIK3CA mutations. Mutations 
in the genes from the same pathway PTEN and 
AKT1 may account for about 25% and 2% of cases 
respectively. 
To be noted 
Molecular targets:  Pan-PI3K inhibitors inhibit all 
four of the PI3K class I isoforms. However, this 
broad range of molecular targets results in an 
increased risk of toxicity and off-target effects. 
Copanlisib is currently the only pan-PI3K inhibitor 
that is approved by the FDA for clinical use in 
treating cancer patients. PI3Kalpha specific 
inhibitors inhibit the activity of the class I PI3K 
catalytic subunit alpha isoform and these can be used 
to target cancers that are dependent on the specific 
PI3K isoform. The PI3Kalpha isoform is often 
activated by PIK3CA mutations and initial clinical 
trials have found greater response to PI3Kalpha 
inhibitors in PIK3CA mutated cancers than wild 
type. These specific isoform inhibitors offer greater 
potential for therapeutic use than nonspecific pan-
PI3K inhibitors because they are expected to have 
fewer off target adverse effects due to the restricted 
expression of different PI3K isoforms in 
nonmalignant cells. PI3Kalpha specific inhibitors 
have yet to be approved for clinical use outside of 
trials although they have reached the advanced 
stages of clinical testing (Janku et al, 2018). 
PI3Kalpha inhibitors seem to result in greater overall 
response rates and longer progression free survival 
within patients that possess PIK3CA mutations than 
without. However, even some patients with PIK3CA 
mutations have shown short response durations to 
PI3Kalpha inhibitors (Juric, 2018).  
Similarly, aspirin use has been associated with the 
blocking of the PI3K pathway resulting in 
suppression of cancer cell growth and induction of 
apoptosis (Uddin, 2010). A meta-analysis suggests 
PIK3CA mutations may be predictive of response to 
aspirin in colorectal cancer although too few studies 
preclude definitive conclusions (Paleari, 2016). 
Current trials randomized by aspirin like add-aspirin 
might be able to validate these findings. 
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